- Post hoc analysis of 70 of 110 severe TBI patients from the BOOST II randomized trial, across ten U.S. ICUs.
- Background electronic ICP data were compared with bedside-identified minimalist episodes (60 minutes or less, tier 1 treatments only), defined as 5 minutes at 20 mm Hg or higher.
- Electronic data confirmed only 47% of 509 bedside-identified episodes, and 76% of the 286 discordant episodes had average electronic ICP below 20 mm Hg.
- The authors conclude bedside identification may not reliably distinguish sustained ICP episodes and propose open-source, real-time, temporally synchronized electronic definitions.
Latest papers
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Secondary analysis of the FIBRES randomized trial, including 735 adults with significant postbypass bleeding and hypofibrinogenemia across eleven Canadian hospitals.
- Fibrinogen concentrate (4 g) was compared with cryoprecipitate (10 units), dosed within 24 hours after cardiopulmonary bypass as needed.
- In non-critically ill patients, FC led to fewer cumulative blood components (mean ratio 0.84, 95% CI 0.73 to 0.96; p=0.01), with a similar pattern in elective surgery patients.
- In elective surgery patients, adverse events (RR 0.85) and serious adverse events (RR 0.71) were less frequent with FC, which the authors suggest may be a safety advantage.
AI summary not available. Read the source abstract on PubMed.
- Single-center randomized trial of 70 children aged 3 to 17 recovering from cardiac catheterization or electrophysiology procedures for congenital heart disease.
- Weighted blankets were compared with standard postprocedure care, with 31 patients in the blanket group and 39 age-matched controls.
- RASS scores and postprocedure sedative use did not differ between groups, so the primary efficacy aim was not met.
- Vital signs did not differ and no adverse events were linked to blanket use, leading the authors to call blankets safe and a possible low-cost nonpharmacologic option.
- Single-center, double-blind, placebo-controlled randomized trial of 160 adults undergoing thyroidectomy under general anesthesia.
- Participants received bilateral superficial cervical plexus blocks with 0.25% bupivacaine or saline, with all receiving multimodal analgesia.
- Quality of recovery (QoR-40) on postoperative day 1 did not differ: 174 versus 173, adjusted mean difference 0.91 (95% CI, -3.57 to 5.40; P = 0.688).
- The bupivacaine group used less PACU opioid (P = 0.017) and fewer needed rescue antiemetics (3 [3.8%] vs 13 [16%]; P = 0.011).
- A secondary analysis of an RCT in 521 adults with chronic low back pain compared cognitive therapy, mindfulness-based stress reduction, and behavior therapy with treatment as usual.
- Hierarchical linear modeling tested whether changes in one psychosocial mechanism in a prior session predicted changes in another mechanism in the next session.
- Lagged prior-session changes predicted next-session changes in other mechanisms, with reciprocal links between pain catastrophizing and self-efficacy and unidirectional links for mindfulness and behavioral activation.
- Individual differences in the strength of these mechanism-to-mechanism relationships predicted pre- to post-treatment outcome changes, though the abstract reports no effect sizes or p values.
- This double-blind randomized trial enrolled 240 adults undergoing open heart surgery via sternotomy who had bilateral indwelling erector spinae catheters, at one large academic hospital.
- Participants were randomized to programmed intermittent boluses or continuous infusion of ropivacaine 0.2% through an electronic pump.
- The primary outcome, 72-hour opioid consumption in OMME, did not differ significantly: 1.08-fold greater with boluses (95% CI, 0.90-1.31; p = 0.40).
- No secondary outcomes differed significantly, and the authors concluded that intermittent boluses did not reduce early opioid use compared with continuous infusion.
- Randomized trial of 2,331 adults with high impact chronic pain, assigned to a remote Health Coach, an online painTRAINER program, or Usual Care Plus, with follow-up at 3, 6, and 12 months.
- Both cognitive behaviorally based self-management arms were compared with Usual Care Plus, which included educational materials only.
- At 6 and 12 months, 36-42% of intervention participants had sustained HICP versus 50-52% of Usual Care Plus participants, with relative risks about 0.8.
- Favorable chronic pain outcomes were more common with interventions at 6 and 12 months (relative risks 1.24-1.44), while 3-month sustained HICP differences were within chance expectation.
- This randomized, patient- and assessor-blinded trial analyzed 109 of 114 enrolled adults undergoing elective laparoscopic or robotic colorectal cancer resection.
- Patients received intravenous lidocaine, intravenous dexmedetomidine, or intrathecal morphine, with plasma MMP-9 at 1 hour postoperatively as the primary outcome.
- MMP-9 was higher with lidocaine than with dexmedetomidine (log-scale difference 0.333; 95% CI 0.0642-0.601; P = .009) and than with intrathecal morphine (0.424; 95% CI 0.0248-0.823; P = .033).
- The authors concluded that the adjuvants had differential effects on biomarkers and immune profiles, and that intrathecal morphine gave superior analgesia; long-term oncologic effects remain unknown.
- Single-center, double-blind randomized trial of 220 patients undergoing noncardiac surgery, comparing dexmedetomidine with saline placebo.
- Dexmedetomidine 1.5 µg/kg/h IV was started 15 minutes before induction and continued until 15 minutes after induction.
- NOX compliance was 90.7% (98/108) with dexmedetomidine versus 12.5% (14/112) with placebo (P < .001). Postoperative NRS >3 was lower at all time points, e.g., 2.8% vs 25.9% at 0 hours.
- Dexmedetomidine also reduced rescue opioid consumption and postoperative nausea and vomiting, and the authors report improved hemodynamic stability and a favorable safety profile.
- Secondary analysis of the PROPPR trial, including 286 severely injured patients with complete data out of 680 enrolled across 12 level 1 centers.
- Early emergency department blood draws were analyzed for 48 coagulation and inflammatory biomarkers, grouped into phenotypes using principal component analysis; no intervention was given.
- The 30-day mortality rate was 24.4% (n = 70); after adjustment, the coagulopathy phenotype was associated with mortality (p = 0.0002), and mixed inflammatory phenotype 3 showed a trend (p = 0.0684).
- The authors conclude that coagulation and inflammation are coactivated early after severe injury and are linked to poor outcomes.
- This subgroup analysis of the MINT trial included 3504 adults with acute myocardial infarction and anemia across 144 sites, of whom 1679 (47.9%) were critically ill.
- Patients were randomized to a restrictive strategy (transfuse at hemoglobin below 7-8 g/dL) or a liberal strategy (below 10 g/dL), with 30-day outcomes compared by ICU status.
- The restrictive strategy showed nonsignificant increases in death in critically ill (RR 1.24; 95% CI 0.95-1.61) and noncritically ill patients (RR 1.09; 95% CI 0.77-1.54); interaction p = 0.55.
- Death and death/MI were more common in critically ill patients at 30 days, and the authors found no evidence that the overall liberal-favoring MINT results differ by ICU status.
- Prospective randomized paired-kidney study at one tertiary center, with 40 recipients from 20 brain-dead donor pairs.
- Recipients were randomized to FloTrac-guided goal-directed therapy targeting stroke volume, or to standard CVP-guided therapy.
- GDHT received less intraoperative IV fluid (1,385.0 ± 259.6 vs 1,958.0 ± 877.0 mL, p = 0.011), and rescue vasopressor use was 45% vs 100% (p = 0.001).
- The authors conclude GDHT safely limits fluid and vasopressor needs, while creatinine trajectories and delayed graft function (10%) were identical between groups.
- Randomized, blinded, two-center French superiority trial of 320 adults undergoing elective cardiac surgery with cardiopulmonary bypass.
- Patients received opioid-free anesthesia with ketamine, dexamethasone, lidocaine and magnesium, or opioid anesthesia with sufentanil.
- The 30-day composite of complications or death occurred in 75.4% versus 84.5% (RR 0.90; 95% CI 0.80 to 0.99; P = 0.049), with a fragility index of 1.
- The authors call the results hypothesis generating; cardiovascular and digestive complications and deaths were also lower with opioid-free anesthesia.
- Single-center, double-blind, placebo-controlled RCT of 384 women aged 18 to 50 undergoing ambulatory surgery under general anesthesia.
- Participants received oral 5 mg olanzapine or placebo, with both groups also receiving dexamethasone and ondansetron prophylaxis.
- Olanzapine raised QoR-40 scores on POD 1 by 9.0 points (95% CI, 6.1 to 11.8; P < 0.001).
- Olanzapine also lowered the odds of any nausea on POD 1 (OR 0.43) and POD 2 (OR 0.48), while PACU length of stay did not differ.
- A prospective randomized trial at a single tertiary university hospital enrolled 57 patients undergoing elective thoracotomy.
- Patients received preoperative ultrasound-guided paravertebral block or erector spinae plane block at T5 with 20 mL of 0.25% bupivacaine, with remifentanil titrated using the NOL index.
- Intraoperative remifentanil use was lower with PVB (431.4 vs 863.6 mcg, p < 0.001), as was 24-hour postoperative morphine (15.2 vs 20.1 mg, p = 0.002).
- Resting NRS scores were lower with PVB at 9 and 12 hours, and cough NRS scores were lower at all time points; the authors conclude ESPB may be insufficient for major thoracic surgery.
- Single-center, double-blind, placebo-controlled randomized trial of 70 adults with delayed recovery after on-pump cardiac surgery in Cairo, Egypt.
- Enteral levothyroxine (25-50 µg/d, titrated by body mass index) versus identical placebo, started on postoperative day 2 and continued until ICU discharge.
- The levothyroxine group had greater GCS improvement (aMD +7.81; 95% CI 5.24-10.38; p<0.001) and lower 30-day mortality (14.3% vs 45.7%; aHR 0.24; 95% CI 0.09-0.65; p=0.005).
- The authors call the mortality finding hypothesis-generating given only 21 events, and hospital stay was longer with levothyroxine (13.1 vs 10.3 days, p=0.005).
- Single-center randomized controlled study of 122 adults aged 60 or older with preoperative Anticholinergic Cognitive Burden scores of 3 or higher undergoing CABG.
- Patients given a deprescribing strategy that avoided perioperative anticholinergic anesthetic and analgesic drugs were compared with standard care that included them.
- At day 90, full Katz Index independence was more frequent with deprescribing (75.0% vs 41.1%, p < 0.001), and frailty scores were lower (median 3 vs 4, p < 0.001).
- Perioperative anticholinergic use was an independent predictor of 90-day total complications (OR 2.430, 95% CI 1.031-5.726, p = 0.042), and the authors call anticholinergic burden a modifiable risk factor.
- Prospective noninferiority RCT of 188 patients with Parkinson's disease randomized 1:1 to undergo elective bilateral deep brain stimulation surgery.
- Desflurane general anesthesia, titrated to electrophysiologic signal quality, was compared with dexmedetomidine conscious sedation.
- High-quality microelectrode recording occurred in 89.4% versus 90.3% (difference -0.96%, 95% CI -9.62 to 7.70), and general anesthesia shortened operative time by 9.07 min (P < 0.001).
- Six-month UPDRS change, levodopa equivalent dose, and complication rates were comparable between groups, and the authors conclude general anesthesia is noninferior.
- Randomized controlled trial in anesthesia residents tested rested and after a 24-hour shift; 35 enrolled, 27 in the primary analysis.
- Sleep-deprived residents were randomized to a 30-minute nap opportunity or control, with actigraphy measuring sleep and nap duration.
- Simulated clinical performance was 14.8 points higher after napping (95% CI 2.8 to 26.9; P = 0.018), while technical skills did not differ significantly.
- The authors conclude napping appears to enhance performance, and exploratory analyses linked longer nap duration to several performance domains.
- Randomized, double-blind, placebo-controlled multicenter trial of 80 patients from five French centers who met VA-ECMO weaning criteria.
- Patients received a single 24-hour levosimendan infusion or placebo; the primary endpoint was weaning failure, defined as no weaning within 48 h, another assist device, or death within 7 days.
- Weaning failure occurred in 25% of patients in both groups (OR 1.00, 95% CI 0.36 to 2.75; P = 1.00).
- Acute kidney injury at day 30 was more frequent with levosimendan (62.5% vs 38.5%; OR 2.67, 95% CI 1.08 to 6.62; P = 0.03), which the authors describe as hypothesis generating.
- Triple-masked, placebo-controlled randomized trial of 50 adults (25 per arm) undergoing outpatient percutaneous nephrolithotomy.
- Participants all received a preoperative single-injection erector spinae block, then were randomized to continuous bupivacaine 0.25% or saline placebo via perineural catheter for about 57 hours.
- Average daily pain (3.5 vs 3.0; difference 0.25, 95% CI -1.0 to 1.5, P=0.538) and cumulative oxycodone (10 vs 15 mg; difference 0, 95% CI -15 to 5, P=0.358) did not differ significantly between groups.
- The authors found no benefit from adding a continuous block; maximum daily pain, sleep disturbance, and Brief Pain Inventory interference also showed no significant differences.
- Retrospective secondary analysis of a single-center randomized trial in 105 adults undergoing cardiac surgery with signs suggesting endothelial dysfunction.
- All patients received 80 ppm inhaled nitric oxide for 24 hours, then NO was given via cardiopulmonary bypass, mechanical ventilation, or nasal cannula, with metHb and uptake compared across these methods.
- Median metHb was 0.6% on bypass, 2.1% on ventilation, and 0.8% on nasal cannula; the metHb rise slope was steeper on ventilation than on bypass (β 8.354 * 10-3 vs 3.738 * 10-3, p < 0.001).
- Estimated NO delivery was higher on ventilation than on bypass (median 25.1 vs 8.2 μmol/min, p < 0.001), and the authors suggest metHb may help guide therapy when extrapulmonary effects are desired.
- Single-center randomized controlled trial in 50 children (general anesthesia alone) and 51 children (general anesthesia plus block), aged 4 to 12, undergoing thoracoscopic mediastinal tumor resection.
- General anesthesia alone was compared with general anesthesia plus a preincision, ultrasound-guided, single-level thoracic paravertebral block.
- 24-hour FLACC pain area under the curve was lower with the block: 41.3/240 vs 53.0/240, mean difference -11.8 (95% CI -14.2 to -9.34; p < 0.001).
- The authors also report higher QoR-15 scores at 24 hours, lower early pain scores, and reduced opioid use and hospital stay with the block.
- Predefined exploratory substudy of the GLORIOUS trial, including 878 adults undergoing nonemergent CABG and/or surgical aortic valve replacement at one tertiary center.
- Patients received restrictive (FiO2 50%) or liberal (FiO2 100%) oxygenation during bypass and the first hour after weaning; lung function was measured before and at 3 months.
- Pulmonary function fell across all measures at 3 months, such as FEV1 by 8.3 percentage points (95% CI 6.6 to 8.3), with no between-group differences (all p > 0.3).
- The authors concluded that restrictive oxygenation did not attenuate the decline and described the findings as hypothesis-generating.
- Double-blind RCT of 220 nulliparous parturients randomized to epidural labor analgesia with warmed (37°C) or room-temperature (22°C) local anesthetic solution.
- Both groups received 0.075% ropivacaine with 0.5 µg/mL sufentanil, differing only in solution temperature.
- Intrapartum fever occurred in 15.5% warmed versus 30.9% room-temperature (RR 0.5, 95% CI 0.298-0.840; P = .007), short of the prespecified 60% reduction target.
- Median maximum temperature was modestly lower in the warmed group, while shivering and all secondary outcomes did not differ significantly.
- Post-hoc secondary analysis of a pilot randomized trial in 42 adults with insomnia and comorbid migraine, mostly female, with a mean age of 43.8 years.
- Insomnia severity, measured by the Insomnia Severity Index (ISI), was modeled as a predictor of migraine disability (MIDAS) and migraine-specific quality of life (MSQv2.1) using linear mixed models.
- Each 1-point rise in ISI was linked to a higher MIDAS rate ratio of 1.10 (95% CI 1.028-1.171, P < .05), and to lower MSQv2.1 scores in restrictive role (B=-1.205, P=.001), preventive role (B=-0.981, P=.020), and emotional function (B=-1.66, P=.001).
- The authors conclude that insomnia severity is significantly associated with migraine disability and quality of life, supporting prevention and sleep intervention in patients with migraine.
- Double-blind randomised controlled trial of 304 patients undergoing elective hepatectomy, 48% of whom had open surgery.
- Patients received lidocaine with low-dose esketamine or placebo from induction to end of surgery, and the active drugs were infused for 72 hours afterward.
- Movement-evoked pain at 24 hours was lower with lidocaine-esketamine (median 3 vs 4, p < 0.001), with moderate-to-severe pain in 34% vs 56% (p < 0.001).
- Sufentanil consumption fell and quality of recovery scores were higher over the first 72 hours, but the authors describe these changes as clinically modest.
- Double-blinded, placebo-controlled RCT at two Danish university hospitals, with 100 of 113 randomized patients undergoing non-emergent CABG analyzed.
- Surgeon-administered intraoperative sternal and chest wall infiltration with bupivacaine, epinephrine, clonidine, and dexamethasone (62.5 mL) was compared with saline placebo.
- No difference in opioid use over the first 24 postoperative hours: median 62.3 mg versus 64.0 mg oral morphine equivalents (p = 0.649).
- No secondary or safety endpoints differed significantly, and the authors concluded the intervention did not reduce opioid consumption or add clinical benefit.
- Post-hoc pooled analysis of two phase III randomized trials in 370 patients undergoing elective gynecological surgery.
- HSK21542, a peripherally restricted kappa-opioid agonist, was compared with placebo and with tramadol, with inverse probability weighting used to balance baseline characteristics.
- HSK21542 reduced pain intensity more than placebo over 12 and 24 hours (least-squares mean differences -8.1 and -16.3, both P < .001), with no significant difference from tramadol.
- Nausea (24.7% vs 66.7%) and vomiting (21.3% vs 60.5%) were lower with HSK21542 than with tramadol; the authors conclude it could give adequate analgesia with few adverse events.
- Multicentre, double-blind randomised trial at two tertiary paediatric surgery centres, enrolling 96 children aged 3 to 15 undergoing laparoscopic appendicectomy (46 TAP, 50 infiltration).
- Ultrasound-guided TAP block was compared with local anaesthetic wound infiltration of trocar sites, both using levobupivacaine and standardised multimodal analgesia including paracetamol, ketoprofen, phloroglucinol and nalbuphine.
- Total 24-hour nalbuphine dose was 0.2 [0.0 to 0.2] mg/kg in both groups (P = 0.95), and FLACC scores did not differ (P = 0.78).
- Time to first nalbuphine dose and time to first mobilisation did not differ significantly (log-rank P = 0.095 and 0.18). The authors concluded TAP block gave no greater opioid-sparing effect than wound infiltration.
- Open-label randomised controlled trial of 148 osteosynthesis patients at a university hospital, comparing a thermal care bundle with control.
- The bundle combined 10-minute prewarming, forced-air warming during and after surgery, a room kept at 21 °C, and fluids warmed to 38 °C.
- At surgery start, hypothermia occurred in 1.3% vs 9.9% of controls (OR 7.59, P=0.021), and at PACU admission in 14.3% vs 29.6% (OR 2.07, P=0.024).
- Wound infections requiring readmission were not significantly reduced (OR 0.35, 95% CI 0.04 to 2.92, P=0.332); presurgery stay and OR/PACU occupancy were SSI risk factors.
- Ancillary analysis of a randomised trial of 66 adults undergoing cardiac surgery with expected prolonged cardiopulmonary bypass (over 90 min) at one French hospital.
- Patients were randomised to intra-operative haemo-adsorption or standard care, with endotoxin mass and activity measured from pre-surgery to 48 hours after surgery.
- Endotoxin mass fell after bypass while relative endotoxin activity rose, and high postoperative activity was linked to dobutamine requirement, inflammatory markers and organ injury; no effect sizes are reported in the abstract.
- The authors conclude that the capacity to inactivate endotoxin, rather than its quantity, may determine harm, and haemo-adsorption did not lower endotoxin mass or activity.
- Single-center RCT of 140 adults undergoing on-pump cardiac surgery, randomized 1:1 to flow-controlled or pressure-controlled ventilation.
- Individualized FCV with compliance-guided PEEP and driving pressure was compared with PCV using the same compliance-guided settings and tidal volumes of 6 to 8 ml/kg predicted body weight.
- Postoperative IL-8 at 6 h after bypass did not differ significantly (3.08 vs 3.60 pg/ml; β 0.08; 95% CI -0.17 to 0.33; P = 0.573), while mechanical power fell by 55% with FCV.
- Pulmonary and extrapulmonary complications were lower and hospital stay shorter with FCV, but these were explorative secondary outcomes that the authors say justify future trials.